2016 European Guidelines on CVD prevention in clinical ...- Teva Pharmaceutical Industries : lipids, hypertension (2015) 11/05/2016 2016 European Guidelines on CVD prevention in clinical

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Thermo Fischer Scientific : Cardiac markers (2014-2015)

- Astra Zeneca : Platelet inhibition (2014-2015)

- Vifor International : Heart failure (2015)

Albus Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Hospital "Porz am Rhein gGmbH", Cologne : Adherence in CHD (2014)

- Servier : Anxiety and Depression in CHD (2014)

- German Diabetes Society : Behaviour change in Diabetes mellitus (2014)

- Self Help Group for patients with Pulmonary Hypertension : Coping with illness (2014)

- German Cardiac Society : Psychocardiology (2014)

- Elsevier : Psychocardiology (2014-2015)

- Deutscher Ärzteverlag : Psychocardiology (2014-2015)

- Schattauer Verlag : Psychotherapy (2014-2015)

- Sanofi Aventis : Adherence in Diabetes mellitus (2015)

- Helios Klinikum, Wuppertal : Anxiety and Depression in CHD (2015)

- Hospital "Rhein Klinik", Bad Honnef : Psychosocial aspects in CHD (2015)

- LVR Klinikum Essen : Psychosocial aspects in CVD (2015)

- PsychotherapeutenForum Aachen eV : Psychosocial aspects in CVD (2015)

- Deutsche Hypertonie Liga : Psychosocial aspects in Hypertension (2015)

- Sportärztebund Nordrhein eV : Psychosocial risk factors in CAD (2015)

D - Research funding (departmental or institutional).- German Research Foundation : Psychotherapy in cardiac patients with depression (2014-2015)

E - Research funding (personal).- German Research Foundation : Psychotherapy in cardiac patients with depression (2014-2015)

11/05/2016

2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

1/35

Binno Simone Nothing to be declared (2014-2015)

Brotons Carlos A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Brilinta (2014)

- Pfizer : Apixaban (2014-2015)

- Bayer : Aspirin (2014-2015)

- Lundbeck : Selincro (2014-2015)

- MSD-Spain : lipids (2015)

Catapano Alberico A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Cardiovascular (2014)

- Astra Zeneca : Cardiovascular (2014)

- Pfizer : Cardiovascular (2014)

- Sanofi Aventis : Cardiovascular (2014)

- Esteve : Cardiovascular (2014)

- Merck Sharp & Dohme : Cardiovascular (2014-2015)

- Kowa : Cardiovascular (2014-2015)

- Recordati International : Cardiovascular (2015)

- Aatra Zeneca : Cardiovascular (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Cardiovascular (2015)

- Pfizer : Cardiovascular (2015)

- Sanofi Aventis : Cardiovascular (2015)

- Aegerion : Cardiovascular (2015)

D - Research funding (departmental or institutional).- Pfizer : Cardiovascular (2015)

11/05/2016




2/35

Catapano Alberico - Sanofi Aventis : Cardiovascular (2015)

- Merck Sharp & Dohme : Cardiovascular (2015)

Cooney Marie Therese Nothing to be declared (2014-2015)

Corra Ugo Nothing to be declared (2014-2015)

Cosyns Bernard B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixaban (2014)

- Bristol Myers Squibb : Apixaban (2014)

- Therabel : molsidomine (2014)

- Zambon : Zanicombo (2014)

- St Jude Medical : Trifecta valve (2015)

D - Research funding (departmental or institutional).- Boehringer-Ingelheim : Dabigatran (2014-2015)

- Johnson & Johnson : MMR nanobodies (2014-2015)

- St Jude Medical : pacing (2014-2015)

Deaton M Christi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : none (2014-2015)

- Boehringer-Ingelheim : none (2014-2015)

- Daiichi Sankyo : none (2014-2015)

- Sanofi Aventis : none (2014-2015)

Graham Ian Maklim A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Advisory Board (2014-2015)

- Merck Sharp & Dohme : CVD risk factor audit (2014-2015)

D - Research funding (departmental or institutional).- Merck Sharp & Dohme : CVD risk factor audit (2014)

E - Research funding (personal).- World Health Organisation : Co-Chair of Expert Advisory Group developing a new CVD risk estimation system (2015)

11/05/2016




3/35

Hall Michael S Nothing to be declared (2014-2015)

Hobbs Richard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : AF (2015)

- Boehringer-Ingelheim : Af (2015)

- Pfizer : Lipids/Anticoag (2015)

C - Receipt of royalties for intellectual property.- Amgen Inc : CV risk and lipids (2014)

- Boehringer-Ingelheim : stroke (2014)

- Pfizer : stroke (2014)

- Bayer Healthcare : stroke (2014)

D - Research funding (departmental or institutional).- Bayer Healthcare : AF screening (2014)

- Pfizer : ;lipids (2015)

Hoes Arno B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)

- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014)

D - Research funding (departmental or institutional).- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We

perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)

11/05/2016




4/35

Hoes Arno - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015)

Lochen Maja-Lisa A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : no kr 4000 for a lecture on snuff (snus) and health effects (2014)

C - Receipt of royalties for intellectual property.- Royalties for 3 medicine books from Gyldendal Akademisk forlag : Medicine books (2015)

Loellgen Herbert Nothing to be declared (2014-2015)

Marques-Vidal Pedro B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Swiss national fund : PhD scholarship (2014-2015)

Perk Joep Nothing to be declared (2014-2015)

Piepoli Massimo Francesco Nothing to be declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015)

- Novartis : Heart Failure Prevention Initiatives (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure Prevention Initiatives (2015)

Prescott Eva Nothing to be declared (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Leo Pharma : Diverse (2014)

- Novo Nordisk : Liraglutide (2014)

Redon Josep A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Diabetes (2014-2015)

- Bristol Myers Squibb : Diabetes (2014-2015)

- Boehringer-Ingelheim : Hypertension (2014-2015)

11/05/2016




5/35

Redon Josep - Menarini : Hypertension (2014-2015)

- MSD : Hypertension (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Hypertension (2014-2015)

Richter Dimitrios A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : CAD- hypertension (2014-2015)

- Novartis : hypertension (2014-2015)

- Abbott : lipids (2014-2015)

- Amgen : lipids (2014-2015)

- Sanofi Aventis : Lipids (2014-2015)

- Lilly : Lipids (2014-2015)

- Unilever : lipids (2014-2015)

- Merck Sharp & Dohme : lipids (2014-2015)

- Angelini : Lipids (2014-2015)

- Vianex : lipids (2014-2015)

- Galenica : Lipids (2014-2015)

- Swisspharma : lipids-hypertension (2014-2015)

- Astra Zeneca : lipids-thrombosis (2014-2015)

- Pfizer : lipids-thrombosis (2014-2015)

- Winmedica : lipids-thrombosis (2014-2015)

- Boehringer-Ingelheim : thrombosis (2014-2015)

- Bayer Healthcare : Thrombosis (2014-2015)

- Teva Pharmaceutical Industries : lipids, hypertension (2015)

11/05/2016




6/35

Sattar Naveed A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : diabetes products (2014)

- Eli Lilly : CETP inhibitor (2014-2015)

- Amgen : PCSK9 (2014-2015)

- Sanofi Aventis : PCSK9 (2014-2015)

- Janssen-Cilag : Diabetes educational talk - not product related (2015)

- Merck Sharp & Dohme : Lipid-lowering (2015)

- Boehringer-Ingelheim : SGLT2 inhibitor (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : GLP-1 trial (2014-2015)

- Hoffman La Roche : IL-6R tocilizumab (2014-2015)

D - Research funding (departmental or institutional).- Roche Pharma : biomarker research (2014-2015)

Smulders Yvo Nothing to be declared (2014-2015)

Tiberi Monica Nothing to be declared (2014-2015)

van der Worp Bart A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Netherlands : DOAC (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : oral anticoagulants; thrombolytic drugs (2014)

D - Research funding (departmental or institutional).- Bard : Therapeutic hypothermia (2014)

Van Dis Ineke Nothing to be declared (2014-2015)

Verschuren Monique Nothing to be declared (2014-2015)

11/05/2016




7/35

Aboyans Victor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)

- Sanofi Aventis : Hyperlipidemia (2014-2015)

- Novartis : Hypertension (2014-2015)

- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)

- Bayer Healthcare : Oral anticoagulation (2014-2015)

- Pfizer/BMS alliance : Oral anticoagulation (2014-2015)

Andersen Karl A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : investigator, hypertension, heart failure, cor art disease (2014-2015)

Attia Ihab A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Hypertension (2014)

- Servier : Hypertension (2014)

- Boehringer ingelhiem : Hypertension (2014)

- Merck Sharp & Dohme : Lipid lowering therapy (2014)

- Bayer AG : Rivaroxaban (2014)

- Astra Zeneca : Ticagrelor (2014)

Declaration not submitted (2015)

Bachl Norbert Nothing to be declared (2014-2015)

Cho Leslie Nothing to be declared (2014-2015)

Colkesen Ersen Nothing to be declared (2014-2015)

Cox John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Investigator - empagliflozin - SGLT2 inhibitor for type 2 diabetes (2014-2015)

Davletov Kairat Nothing to be declared (2014-2015)

De Backer Guy Nothing to be declared (2014)

14/09/2016

Guidelines on CVD Prevention 2016 (TF14) - Reviewers



8/35

De Backer Guy A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : Lipid lowering drugs (2015)

- Sanofi Aventis : Lipid lowering drugs (2015)

De Maeyer Catherine B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Hypertension (2014-2015)

- Sanofi Aventis : Hypercholesterolemia (2015)

De Sutter Johan Nothing to be declared (2014)

D - Research funding (departmental or institutional).- Medtronic : heart failure (2015)

- Novartis : heart failure (2015)

Delagardelle Charles Nothing to be declared (2014-2015)

Dilic Mirza Nothing to be declared (2014-2015)

Duishvili Davit Nothing to be declared (2014-2015)

Egidi Guenther Nothing to be declared (2014-2015)

Ferrieres Jean A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab (2014-2015)

- Amgen : evolocumab (2014-2015)

- Merck Sharp & Dohme : ezetimibe (2014-2015)

- Cerenis therapeutics : Atherosclerosis (2015)

D - Research funding (departmental or institutional).- Amgen : none (2014)

- Medispec Limited : none (2014)

Filipova Slavomira A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : investigator - multicentric trial (2014)

- Amgen Inc : investigator - multicentric trial, national investigator, International Steering Commitee (2014)

- Servier : investigator - multicentric trial, speaker fees (2014)

14/09/2016




9/35

Filipova Slavomira B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : investigator - multicentric trial (2014)

- Amgen Inc : investigator - multicentric trial, national investigator (2014)

Declaration not submitted (2015)

Fisher Miles A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : albiglutide (2014-2015)

- Astra Zeneca : all diabetes products (2014-2015)

- Janssen-Cilag : canagliflozin (2014-2015)

- Sanofi Aventis : glagine, lixisenatide (2014-2015)

- Boehringer Ingelheim / Eli Lilly : linagliptin, empaglifozin, dulaglutide, glargine (2014-2015)

- Novo Nordisk : liraglutide, degludec (2014-2015)

- MSD : sitagliptin (2014-2015)

D - Research funding (departmental or institutional).- Janssen-Cilag : canaglifozin (2014-2015)

Fitzsimons Donna A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)

- Amgen : lipid management (2015)

Franco Duran Oscar A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Metagenics : Nutrition and genetics (2015)

D - Research funding (departmental or institutional).- Nestle : Nutrition (2015)

- Metagenics : Nutrition and genetics (2015)

E - Research funding (personal).- Metagenics : Lifestyle (2014)

- Nestle : Nutrition (2014)

Gale Christopher Peter A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Acute Coronary Syndrome (2014)

14/09/2016




10/35

Gale Christopher Peter - Novartis : Anti VEGF therapy (2014)


Gherasim Daniel Nothing to be declared (2014-2015)

Giga Vojislav A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cardio3 Biosciences : Stem cells in HF (2014-2015)

D - Research funding (departmental or institutional).- Ministry of Science and Education of the Republic of Serbia : Educational grant (2014-2015)

Gruev Ivan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Berlin Chemie AG : hypertension (2014)

- Pfizer : hypertension, dyslipidemia (2014)

- Actavis : hypertension, dyslipidemia (2014)

- Servier : hypertension (2014-2015)

- Egis Pharma : hypertension (2014-2015)

- Novartis : herat failure (2015)

- Sanofi Aventis : ischemic heart disease (2015)

- Bayer : rivaroxaban (2015)

Guenoun Maxime A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiology (2014-2015)

- Boehringer-Ingelheim : cardiology (2014-2015)

- Pfizer : cardiology (2014-2015)

- Servier : cardiology (2014-2015)

- Meda pharma : cardiology (2014-2015)

- Bayer Healthcare : cardiology (2014-2015)

- Bristol Myers Squibb : cardiology (2014-2015)

14/09/2016




11/35

Guenoun Maxime - Medtronic : pacing (2014-2015)

- Sorin Group : pacing (2014-2015)

Gustafsson Ida A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : speaker fee (diabetes and CV disease) (2014-2015)

- Boehringer-Ingelheim : Single advisory board meeting (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GlaxoSmithKline : co-investigator in trial of albiglutide (2014-2015)

- Novartis : co-investigator in trial of aliskeren (2014-2015)

- Novartis : investigator in trial of LCZ696 (heart failure) (2014-2015)

- Astra Zeneca : investigator in trial of ticagrelor (2014-2015)

Hambrecht Rainer A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : eliquis (2014)

- Lilly : prasugrel (2014-2015)

- Berlin Chemie AG : ranolazin (2014-2015)

- Astra Zeneca : ticagrelor (2014-2015)

- Merck Sharp & Dohme : tredaptive (2014-2015)

- The Medicine Company : bivalirudine (2015)

D - Research funding (departmental or institutional).- Medicines Company : Bivalirudin (2014-2015)

Jankowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Antithrombotic drugs (2014)

- Adamed : Cardiology (2014)

- Astra Zeneca : Cardiology (2014)

- Polpharma : Cardiology (2014)

- Sanofi Aventis : Cardiology (2014)

14/09/2016




12/35

Jankowski Piotr - Krka Pharma : Cardiology (2014)

- Sandoz : Hypertension (2014)

- Amgen : Hypercholesterolemia (2014-2015)

- Servier : Hypertension (2014-2015)

- Boehringer-Ingelheim : Atrial fibrillation (2015)

- Sanofi Aventis : Hypercholesterolemia (2015)

Jashari Fisnik Nothing to be declared (2014-2015)

Jennings Catriona Sian Nothing to be declared (2014-2015)

Jug Borut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Heart failure (2014)

- Amgen : Dyslipidemia management (2014-2015)

- Abbott Laboratories : Dyslipidemia management (2014-2015)

- Krka Pharma : Dyslipidemia management & heart failure (2014-2015)

- Novartis : Heart failure (2014-2015)

- Servier : Heart failure (2014-2015)

- Astra Zeneca : CVD prevention (2015)

Kerimkulova Alina Nothing to be declared (2014-2015)

Kiessling Anna Nothing to be declared (2015)

D - Research funding (departmental or institutional).- Stockholm County Council : Medical education research, not related to a specific product or therapeutic area (2014)

Klimiashvili Zurab A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2014-2015)

Kostova Nela Nothing to be declared (2014-2015)

Kotseva Kornelia Nothing to be declared (2014)

14/09/2016




13/35

Kotseva Kornelia D - Research funding (departmental or institutional).- European Society of Cardiology : Research grants from the ESC to IC London for the EUROASPIRE IV and V surveys

(2015)

Mach Francois Nothing to be declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure (2015)

- Menarini : Hypertension (2015)

- Amgen : Lipid lowering (2015)

- Sanofi Aventis : Lipid lowering (2015)

- Merck Sharp & Dohme : Lipid lowering (2015)

- Astra Zeneca : Lipid lowering, Hypertension, Heart Failure (2015)

- Daiichi Sankyo : Lipid lowering, NOAC (2015)

- Pfizer : Lipid lowering, NOAC (2015)

- Bayer : NOAC (2015)

- Boehringer-Ingelheim : NOAC (2015)

- Bristol Myers Squibb : NOAC (2015)

D - Research funding (departmental or institutional).- Amgen : Lipid lowering (2015)

- Merck Sharp & Dohme : Lipid lowering (2015)

Magri Caroline Jane Nothing to be declared (2014-2015)

Mahdhaoui Abdallah Nothing to be declared (2014-2015)

Mancia Giuseppe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : carddiovascular area (2014)

- Servier : cardiovascular area (2014)

- Ferrer Internacional : cardiovascular area (2014)

14/09/2016




14/35

Mancia Giuseppe - Merck Sharp & Dohme : cardiovascular area (2014)

- Recordati International : cardiovascular area (2014)

- Boehringer Ingelheim : cardiovascular area (2014)

- Novartis Pharma : cardiovascular area (2014)

- Bayer AG : Antihyperensive Treatment (2015)

- Merck Sharp & Dohme : Antihypertensie Treatment (2015)

- Boehringer-Ingelheim : Antihypertensive Treatment (2015)

- Covidien : Antihypertensive Treatment (2015)

- Daiichi Sankyo : Antihypertensive Treatment (2015)

- Novartis : Antihypertensive Treatment (2015)

- Menarini : Antihypertensive Treatment (2015)

- Actavis : Antihypertensive Treatment (2015)

- Medtronic Foundation : Antihypertensive Treatment (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Antihypertensie Treatment (2015)

- Sanofi Aventis : Antihypertensive Treatment (2015)

- Recordati International : Antiihypertensive Treatment (2015)

Martin Franz Nothing to be declared (2014)

C - Receipt of royalties for intellectual property.- Biomedal SL : Celiac Disease (2015)

D - Research funding (departmental or institutional).- Spanish Ministry of Science : Type 2 Diabetes and NAFLD (2015)

Metzler Bernhard Nothing to be declared (2014-2015)

Mezzani Alessandro Nothing to be declared (2014-2015)

14/09/2016




15/35

Milicic Davor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular drugs (2014)

- Boehringer-Ingelheim : cardiovascular drugs (2014)

- Pfizer : cardiovascular drugs (2014)

- Sanofi Aventis : cardiovascular drugs (2014)

- Bayer Healthcare : cardiovascular drugs (2014)

- Krka Pharma : cardiovascular drugs (2014)

- Pliva, : cardiovascular drugs (2014)

- Thoratec : mechanical circulatory support (2014)

- Marck Medical : mechanical circulatory support (2014)

- Roche Diagnostics : Biomarkers (2015)

- Heartware : LVAD (2015)

- Boehringer-Ingelheim : NOACS (2015)

- Bayer Healthcare : NOACS (2015)

- Amgen : PCSK9 inhibitors (2015)


E - Research funding (personal).- University of Zagreb : Platelet reactivity to antithrombotic drugs (2014)

Mintale Iveta A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : speaker fees (2014-2015)

- Servier : speaker fees (2014-2015)

- Berlin Chemie AG : speaker fees (2014-2015)

- Merck Serono : speaker fees (2014-2015)

Najafov Ruslan Nothing to be declared (2014-2015)

14/09/2016




16/35

Nedogoda Sergey A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : Arterial hypertension (2014-2015)

- Servier : Arterial hypertension (2014-2015)

- Takeda Pharmaceuticals : Diabetes (2014-2015)

- Astra Zeneca : Diabetes, pulmo (2014-2015)

- Boehringer-Ingelheim : Pulmo (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Arterial Hypertension (2014-2015)

- Astra Zeneca : Diabetes, pulmo (2014-2015)

- Boehringer-Ingelheim : Pulmo (2014-2015)

Nesukay Elena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : cardiology (2014-2015)

Niessner Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : anticoagulation (2014-2015)

- Boehringer-Ingelheim : anticoagulation (2014-2015)

- Daiichi Sankyo : anticoagulation (2014-2015)

- Pfizer : anticoagulation (2014-2015)

- Bristol Myers Squibb : anticoagulation (2014-2015)

D - Research funding (departmental or institutional).- Boehringer-Ingelheim : atrial fibrillation (2014-2015)

Novo Salvatore Nothing to be declared (2015)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- MSD : Statins (2014)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Apixaban (2014)

Oukerraj Latifa Nothing to be declared (2014-2015)

14/09/2016




17/35

Palma Dos Reis Roberto Jose

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Meda pharma : Several products, main OTCs. Some cardiovascular drugs (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : I have participated in Improove it (Clinical trial), as Primmary Investigator (2014)

Petrulioniene Zaneta A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Arterial hypertension (2014)

- Novartis : Arterial hypertension (2014)

- Krka Pharma : Dyslipidaemia (2014)

- Grindex : Heart failure (2014)

- Pfizer : Dyslipidaemia (2015)

- Sanofi Aventis : Dyslipidaemia (2015)

- Novartis : Heart failure (2015)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)

- Boehringer-Ingelheim : anticoagulant (2014)

- Respicardia : anticoagulant (2014)

- Johnson & Johnson : heart failure (2014)

- Pfizer : heart failure, anticoagulant (2014)

- MSD : lipids (2014)

- Abbott Vascular : devices (2014-2015)

- Novartis : heart failure (2014-2015)

- Cardiorentis : heart failure (2014-2015)

- Bayer Healthcare : heart failure (2014-2015)

- Vifor Pharma ltd : heart failure (2014-2015)

14/09/2016




18/35

Ponikowski Piotr - CIBIEM : heart failure (2014-2015)

- Servier : heart failure, coronary artery disease (2014-2015)

- Amgen : heart failure, lipids (2014-2015)

- Boehringer-Ingelheim : anticoagulant, diabetes (2015)

- Respicardia : devices (2015)

- BioControl : devices (2015)

- DC Device : devices (2015)

- Celladon : heart failure (2015)

- Pfizer : lipids (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)

- Vifor Pharma ltd : heart failure (2014)


- Respicardia : anticoagulant (2014-2015)




- CIBIEM : heart failure (2014-2015)






14/09/2016




19/35

Rauch Bernhard B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : cryoablation (2014)

- Novartis : clinical trial on drug therapy (2015)

- Abbott : coronary stents (2015)

D - Research funding (departmental or institutional).- Pfizer : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)

- Deutsche Herzstiftung : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)

- Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauferkrankungen, e.V. , DGPR : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)

- Pfizer : cardiac rehabilitation (2015)

- Deutsche Herzstiftung : cardiac rehabilitation (2015)

- German Society of Cardiovascular Prevention and Rehabilitation : cardiac rehabilitation (2015)

Rodriguez Padial Luis A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)

- Pfizer : Atrial fibrillation (2014-2015)

- Astra Zeneca : CAD (2014-2015)

- Servier : CHF (2014-2015)

- Rovi : Ivabradine (2014-2015)

- Merck Sharp & Dohme : Lipids (2014-2015)

- Lacer : diltiazem (2015)

- Daiichi Sankyo : Hypertension (2015)

D - Research funding (departmental or institutional).- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)

- Bayer : Atrial fibrillation (2015)

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Johnson & Johnson : coronary catheters (2014-2015)

14/09/2016




20/35

Roffi Marco - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015)

D - Research funding (departmental or institutional).- Biosensors : devices (2014-2015)

- Boston Scientific : devices (2014-2015)

- Medtronic : devices (2014-2015)

- Biotronik : devices (2014-2015)


- Terumo Inc : devices (2015)

Rudi Victor Nothing to be declared (2014-2015)

Ryden Lars A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Diabetes and cardiovascular disease. Advisory committee fee (2014)

- Sanofi Aventis : Advisory Board and lectures (2014-2015)

- Merck Sharp & Dohme : Cardiology; Course organisation, lecture (2014-2015)

- Boehringer Ingelheim Pharma GmbH & Co. KG : Diabetes and cardiovascular disease. Expert committee work. (2014-2015)

- Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2014-2015)

- Bayer : Diabetes and cardiovascular disease; Lecture fees (2014-2015)

D - Research funding (departmental or institutional).- Bayer : Pharma (2015)

- Boerhinger Ingelheim : Pharma (2015)

- Novo-Nordic : Pharma (2015)

Saade Georges A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Serono : Speaker Fee (2014)

- Boehringer-Ingelheim : Speaker fees (2014)

- Bayer, : NOAC (2015)

14/09/2016




21/35

Saade Georges B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Committee Member (2014)

D - Research funding (departmental or institutional).- Sanofi Aventis : LMWH (2015)

E - Research funding (personal).- Pfizer : Research (2014)

Schirmer Henrik Nothing to be declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Merck Sharp & Dohme : Cholesterol lowering ezetemib (2015)

Stauder Adrienne Nothing to be declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Teva Pharmaceutical Industries : Parkinsons Disease / speakers fee (2015)

Stelmashok Valeriy A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic Foundation : I took part on Medtronic Advisory Board Meeting (2014)

- Medtronic : advisory board team member (2015)

Szabados Eszter Nothing to be declared (2014-2015)

Tsioufis Costas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Honoraria, Travel Expenses (2014-2015)

- Bayer : Honoraria, Travel Expenses (2014-2015)

- Boehringer-Ingelheim : Honoraria, Travel Expenses (2014-2015)

- Medtronic : Honoraria, Travel Expenses (2014-2015)

- Novartis : Honoraria, Travel Expenses (2014-2015)

- Pfizer : Honoraria, Travel Expenses (2014-2015)

- St Jude Medical : Honoraria, Travel Expenses (2014-2015)

- Sanofi Aventis : Honoraria, Travel Expenses (2014-2015)

- Menarini : Honoraria, Travel Expenses (2014-2015)

14/09/2016




22/35

Tsioufis Costas D - Research funding (departmental or institutional).- Recordati International : Funding (2014-2015)

- St Jude Medical : Renal denervation (2014-2015)

Turc Guillaume Nothing to be declared (2014-2015)

Ural Dilek B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : Apixabane (2014)

- Novartis : Heart failure (investigator in clinical trials and member of local advisory board) (2014)

- Novartis : Amlodipin-valsartan combination (2015)

- Pfizer : Apixaban (2015)

- Merck Sharp & Dohme : Ezetimibe (2015)

- Novartis : LCZ696 (2015)

Vaughan Carl A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : pharmacologic therapy (2014)

- Astra Zeneca, Novartis : pharmacologic therapy (2015)

Vaverkova Helena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : alirocumab - consultancy (2014)

- Amgen s.r.o. Praha : evolocumab - advisory board (2014-2015)

- Merc Sharp and Dohme s.r.o. Praha : ezetimibe - advisory board (2014-2015)

- AOP OrOrphan Pharmaceuticals AG, Praha : lomitapide - consultancy (2014-2015)

- Sanofi Aventis : alirocumab - congress (2015)

Wiklund Olov A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : cardiovascular prevention (2014)

- Astra Zeneca : Cardiovascular prevention (2014-2015)

- Boehringer-Ingelheim : Cardiovascular prevention (2014-2015)

- Amgen Inc : cardiovascular prevention (2014-2015)

14/09/2016




23/35

Wiklund Olov - Merck Sharp & Dohme : cardiovascular prevention (2014-2015)

D - Research funding (departmental or institutional).- Quintiles : Diabetes (2014)

- Astra Zeneca : Basic cardiovascular (2014-2015)

- DuPont : Cardiovascular (2014-2015)

- Cebix inc : Diabetes (2014-2015)

- Sanof-Aventis : Cartdiovascular (2015)

Zafrir Barak Nothing to be declared (2014-2015)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

14/09/2016




24/35

Zavatta Marco Nothing to be declared (2014-2015)

14/09/2016




25/35

Aboyans Victor A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)

- Sanofi Aventis : Hyperlipidemia (2014-2015)

- Novartis : Hypertension (2014-2015)

- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)

- Bayer Healthcare : Oral anticoagulation (2014-2015)

- Pfizer/BMS alliance : Oral anticoagulation (2014-2015)

Achenbach Stephan Nothing to be declared (2015)

D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2014)

Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Thermo Fischer Scientific : Cardiac markers (2014-2015)

- Astra Zeneca : Platelet inhibition (2014-2015)

- Vifor International : Heart failure (2015)

Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- MSD-España : Lipids (2014)

- Sanofi Aventis : lipids (2014-2015)

- Burson Masteller : nutrition (2014-2015)

- Astra Zeneca : thrombosis (2014-2015)

D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015)

Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2014)

- Boehringer-Ingelheim : Anticoagulation (2014-2015)

- Daiichi Sankyo : Anticoagulation (2014-2015)

- Pfizer : Anticoagulation (2014-2015)

11/05/2016

Committee for Practice Guidelines 2014-2016 - MEMBERS



26/35

Baron Esquivias Gonzalo - Merck Sharp & Dohme : Dyslipemia (2015)

Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)

- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)

- Edwards Lifesciences : transcatheter valve implantation (2014-2015)

- Direct Flow Medical : transcatheter valve implantation (2014-2015)

- Gore : Occluders for shunt closure (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015)

- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)

- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)

- Edwards Lifesciences : transcatheter valve implantation (2014-2015)

- Direct Flow Medical : transcatheter valve implantation (2014-2015)

- Gore : Occluders for shunt closure (2015)

Bax Jeroen Nothing to be declared (2014-2015)

Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Aspirin, rivaroxaban (2014)

- Menarini : Ranolazine (2014)

- Novartis : Serelaxin (2014)

- Pfizer : Apixaban (2014-2015)

- Bristol Myers Squibb : Apixaban (2014-2015)

- Sanofi Aventis : Clopidogrel (2014-2015)

- Servier : ivabradine (2014-2015)

11/05/2016




27/35

Bueno Hector - Daiichi Sankyo : Prasugrel (2014-2015)

- Eli Lilly : Prasugrel (2014-2015)

- Astra Zeneca : Ticagrelor (2014-2015)

- Bayer Healthcare : Aspirin (2015)

- Novartis : Serelaxin, LCZ696 (2015)

- Ferrer Internacional : Trinomia (polypill) (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Ticagrelor (2015)

E - Research funding (personal).- Astra Zeneca : Ticagrelor (2014-2015)

Carerj Scipione Nothing to be declared (2014-2015)

Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2014-2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2014-2015)

Fitzsimons Donna A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)

- Amgen : lipid management (2015)

Gaemperli Oliver A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)

- Abbott Vascular : MitraClip (2015)

- Biosensors : Travel Grant to AsiaPCR 2015 (2015)

Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : cardiovascular (2014)

- Pfizer : cardiovascular (2014)

- Bristol Myers Squibb : cardiovascular (2014)

11/05/2016




28/35

Kirchhof Paulus - Boehringer-Ingelheim : cardiovascular (2014-2015)

- Medtronic : cardiovascular (2014-2015)

- St Jude Medical : cardiovascular (2014-2015)

- Sanofi Aventis : cardiovascular (2014-2015)

- Meda pharma : cardiovascular (2014-2015)

- Merck Sharp & Dohme : cardiovascular (2014-2015)

- Medscape : cardiovascular (2014-2015)

- Astra Zeneca : cardiovascular (2015)

- Servier : cardiovascular (2015)

- Bayer Healthcare : cardiovascular (2015)

- Bayer Vital : cardiovascular (2015)

- Correvio : cardiovascular (2015)

- Daiichi Sankyo Europe : cardiovascular (2015)

- Bristol Myers Squibb Global : cardiovascular (2015)

- Pfizer Global : cardiovascular (2015)

- Pfizer Germany : cardiovascular (2015)

D - Research funding (departmental or institutional).- Daiichi Sankyo : cardiovascular (2014-2015)

- St Jude Medical : cardiovascular (2014-2015)

- Sanofi Aventis : cardiovascular (2014-2015)

- Meda pharma : cardiovascular (2014-2015)

- British Heart Foundation : cardiovascular (2014-2015)

- BMS / Pfizer alliance : cardiovascular (2014-2015)

11/05/2016




29/35

Kirchhof Paulus - Leducq Foundation : cardiovascular (2014-2015)

- European Union FP7 : cardiovascular (2014-2015)

- European Union horizon2020 : cardiovascular (2014-2015)

- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)

- UK Medical Research Council : cardiovascular (2015)

Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet agents (2014-2015)

- B.Braun : Surgical instruments (2014-2015)

D - Research funding (departmental or institutional).- Edwards Lifesciences : Cardiac valves (2014-2015)

- Medtronic : Cardiac valves (2014-2015)

Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : nebivolol (2014)

- St Jude Medical : Echo course (2015)

- Servier : Imaging Ischemic disease (2015)

- Boston Scientific : Sudden death (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : CRT (2014)

- Servier : procoralan (2014)

- Bayer : NOAC (2015)

Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : atrial fibrillation (2014-2015)

- Biotronik : atrial fibrillation (2014-2015)

- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)

- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)

11/05/2016




30/35

Lip Gregory Y H - Pfizer : atrial fibrillation, thrombosis (2014-2015)

- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)

- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)

D - Research funding (departmental or institutional).- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)

Nihoyannopoulos Petros Nothing to be declared (2014-2015)

Piepoli Massimo Francesco Nothing to be declared (2014)

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015)

- Novartis : Heart Failure Prevention Initiatives (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Heart Failure Prevention Initiatives (2015)

Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)

- Boehringer-Ingelheim : anticoagulant (2014)

- Respicardia : anticoagulant (2014)

- Johnson & Johnson : heart failure (2014)

- Pfizer : heart failure, anticoagulant (2014)






- Vifor Pharma ltd : heart failure (2014-2015)

11/05/2016




31/35

Ponikowski Piotr - CIBIEM : heart failure (2014-2015)



- Boehringer-Ingelheim : anticoagulant, diabetes (2015)

- Respicardia : devices (2015)




- Pfizer : lipids (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : acute coronary syndrome (2014)

- Vifor Pharma ltd : heart failure (2014)


- Respicardia : anticoagulant (2014-2015)




- CIBIEM : heart failure (2014-2015)






11/05/2016




32/35

Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Johnson & Johnson : coronary catheters (2014-2015)

- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015)

D - Research funding (departmental or institutional).- Biosensors : devices (2014-2015)

- Boston Scientific : devices (2014-2015)

- Medtronic : devices (2014-2015)

- Biotronik : devices (2014-2015)


- Terumo Inc : devices (2015)

Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)

- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)

- Lilly : pulmonary arterial hypertension - ambrisentan (2014)

- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015)

- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2014-2015)

- Teva Pharmaceutical Industries : anti-cancer treatment (2015)

- Sanofi Aventis : anticoagulants (2015)

- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2014-2015)

Vaz Carneiro Antonio Nothing to be declared (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2014)

Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly : Antiplatelet therapy (2014)

11/05/2016




33/35

Windecker Stephan - Bayer Healthcare : Antithrombotic drug (2014)

- Abbott : Stent and Heartvalvetherapy (2014)

- Biosensors : Stents (2014)

- Boston Scientific : Stents (2014)

- Astra Zeneca : Antiplatelet therapy (2014-2015)

- Daiichi Sankyo : Antiplatelet therapy (2015)

- Boston Scientific : Complex PCI (2015)

- Sanofi Aventis : Managing Dyslipidemia (2015)

D - Research funding (departmental or institutional).- Medicines Company : Antithrombotic therapy (2014)

- Johnson & Johnson : Catheters (2014)

- Edwards Lifesciences : Heartvalves (2014)

- St Jude Medical : OCT (2014)

- Abbott : Stent (2014)

- Biotronik : Stent (2014)

- Boston Scientific : Stent and Heartvalves (2014)

- Medtronic : Stent and Heartvalves (2014)

- Sorin Group : Electrophysiology (2015)

- Biotronik : Electrophysiology (2015)

- Johnson & Johnson : Electrophysiology and PCI (2015)

- Guerbet : Imaging (2015)

- Novartis : IMP (2015)

- Actelion : IMP (2015)

11/05/2016




34/35

Windecker Stephan - Medicines Company : IMP (2015)

- Merck Sharp & Dohme : IMP (2015)

- St Jude Medical : PCI (2015)

- Abbott : PCI and Structural Heart Disease (2015)

- Boston Scientific : Structural Heart Disease (2015)

- Edwards Lifesciences : Structural Heart Disease (2015)

- Symetis SA : Structural Heart Disease (2015)

- Medtronic : Structural Heat Disease (2015)

Zamorano Gomez Jose Luis

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Philips : 3D echo (2014)

- Toshiba medical imaging : fusion imaging 3D echo CT (2014)

- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)

- MSD : CV risk factors (2014-2015)

- Abbott : Lecturing (2015)

- Pfizer : Lecturing (2015)

- Sorin Group : Respicardia echo protocol (2015)

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Siemens Healthcare : 3d echo software and free style echo (2014-2015)

- Toshiba medical imaging : Fusion Imaging (2015)

D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)

- Novartis : Clinical trial (2014-2015)

- Ikaria : Clinical trial (2014-2015)

11/05/2016




35/35

Documents

2016 European Guidelines on CVD prevention in clinical ...- Teva Pharmaceutical Industries : lipids, hypertension (2015) 11/05/2016 2016 European Guidelines on CVD prevention in clinical